Drug Profile
Infliximab biosimilar - Axxo
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator AXXO
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Autoimmune disorders; Crohn's disease
Most Recent Events
- 26 Sep 2013 Investigation in Autoimmune disorders in Germany (IV)
- 26 Sep 2013 Investigation in Crohn's disease in Germany (IV)